MedPath

Role of L-Ornithine L-Aspartate in cirrhosis patients with Hepatic Encephalopathy

Not Applicable
Conditions
Health Condition 1: K740- Hepatic fibrosis
Registration Number
CTRI/2019/06/019842
Lead Sponsor
Dr Shalimar
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Closed to Recruitment of Participants
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1) Patients with Overt HE (more than grade II)

Exclusion Criteria

1)Age < 18 and > 65 years

2)Acute liver failure

3)Serum creatinine > 1.5

4)Active alcohol consumption over the past 4 weeks

5)Infections other than SBP, e.g. pneumonia, frank sepsis

6)Ileus, intestinal obstruction

7)Hepatocellular carcinoma

8)Advanced cardiac or pulmonary disease

9)Underlying chronic kidney disease

10)Associated psychiatric illness

11)Pregnant or lactating women

12)Metabolic encephalopathy

13)Degenerative neurological disease

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath